Novo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 1 May 2024 – On 6 February 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024.
Under the programme initiated 6 February 2024, Novo Nordisk will repurchase B shares for an amount up to DKK 2.1 billion in the period from 6 February 2024 to 30 April 2024. The programme is now concluded.
Since the announcement 22 April 2024, the following transactions have been made:
| Number of B shares | Average purchase price | Transaction value, DKK | |
| Accumulated, last announcement | 2,133,500 | 1,846,074,351 | |
| 22 April 2024 | 42,000 | 859.57 | 36,101,805 |
| 23 April 2024 | 42,000 | 881.98 | 37,043,211 |
| 24 April 2024 | 41,000 | 885.25 | 36,295,249 |
| 25 April 2024 | 41,000 | 861.96 | 35,340,459 |
| 26 April 2024 | 41,800 | 875.20 | 36,583,526 |
| 29 April 2024 | 41,000 | 886.30 | 36,338,345 |
| 30 April 2024 | 40,700 | 888.37 | 36,156,603 |
| Accumulated under the programme | 2,423,000 | 2,099,933,547 |
The details for each transaction made under the share repurchase programme are published on novonordisk.com.
Transactions related to Novo Nordisk’s incentive programmes have resulted in a net transfer from Novo Nordisk of 17,988 B shares in the period from 22 April 2024 to 30 April 2024. The shares in these transactions were not part of the Safe Harbour repurchase programme.
With the transactions stated above, Novo Nordisk owns a total of 3,945,719 B shares of DKK 0.10 as treasury shares, corresponding to 0.1% of the share capital. The total amount of A and B shares in the company is 4,446,500,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to DKK 20 billion during a 12-month period beginning 6 February 2024. As of 30 April 2024, Novo Nordisk has since 6 February 2024 repurchased a total of 2,423,000 B shares at an average share price of DKK 866.67 per B share equal to a transaction value of DKK 2,099,933,547.
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 63,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com,Facebook, Instagram, X, LinkedIn andYouTube.
Contact for further information
| Media: | |
| Ambre James-Brown +45 3079 9289 abmo@novonordisk.com | Liz Skrbkova (US) +1 609 917 0632 lzsk@novonordisk.com |
| Investors: | |
| Daniel Muusmann Bohsen +45 3075 2175 dabo@novonordisk.com | Jacob Martin Wiborg Rode +45 3075 5956 jrde@novonordisk.com |
| David Heiberg Landsted +45 3077 6915 dhel@novonordisk.com | Mark Joseph Root (US) +1 848 213 3219 mjhr@novonordisk.com |
| Sina Meyer +45 3079 6656 azey@novonordisk.com | Frederik Taylor Pitter +45 3075 8259 fptr@novonordisk.com |
Company announcement No 34 / 2024
Attachments
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
IDEX Biometrics ASA - Key information relating to possible subsequent offering/repair issue16.5.2024 00:18:52 CEST | Press release
Oslo, 15 May 2024 Reference is made to the stock exchange notice from IDEX Biometrics ASA ("IDEX" or the "Company") on 15 May 2024 regarding a private placement of shares in the Company raising approximately NOK 55 million at a subscription price of NOK 1.65 per share (the "Private Placement") and a possible subsequent offering, raising up to NOK 13,200,000, at the same subscription price as in the private placement (the "Subsequent Offering"), subject to approval by an Extraordinary General Meeting to be held on or about 12 June 2024. Date on which the terms and conditions of the repair issue were announced: 15 May 2024; Last day including right: 15 May 2024; Ex-date: 16 May 2024; Record date: 21 May 2024; Date of approval: Expected to be on or about 12 June 2024 by resolution of an Extraordinary General Meeting (to be called); Maximum number of new shares: 8,000,000; and Subscription price: NOK 1.65. The Subsequent Offering will be carried out as set out in an offering prospectus (wh
Euro Manganese Reports Second Fiscal Quarter 2024 Financial Results15.5.2024 23:59:00 CEST | Press release
VANCOUVER, British Columbia, May 15, 2024 (GLOBE NEWSWIRE) -- Euro Manganese Inc. (TSX-V and ASX: EMN; OTCQB: EUMNF; Frankfurt: E06) (the "Company" or "EMN") today announced financial results and key developments during the second fiscal quarter and to date. The Company has now filed its March 31, 2024, second fiscal quarter Financial Statements and Management’s Discussion and Analysis. Euro Manganese’s fiscal year end is September 30. Key Developments During and Subsequent to the Quarter Chvaletice Project, Czech Republic Chvaletice Manganese Project ("Chvaletice Project" or the "Project") was formally listed as under appraisal for debt financing with the European Investment Bank ("EIB"). Funding from the EIB would complement a broader funding package to support the development of the Company’s high-purity battery-grade manganese plant in the Czech RepublicReceived approval of the Environmental and Social Impact Assessment ("ESIA") for the Chvaletice Project from the Czech Ministry of
Grant of Incentive Subscription Rights in IDEX Biometrics 15 May 202415.5.2024 23:44:07 CEST | Press release
The board of directors of IDEX Biometrics ASA resolved on 15 May 2024 to issue 40,900 incentive subscription rights to a new individual contractor in the IDEX Biometrics group. The grant was made under the company's 2023 incentive subscription rights plan as resolved at the annual general meeting on 23 May 2023. The exercise price of the subscription rights is NOK 1.80 per share and the SRs vest by 25% per year over four years. The SRs expire on 23 May 2028. Following the grant there are 17,514,625 subscription rights outstanding in IDEX Biometrics. For further information contact: Marianne Bøe, Head of Investor Relations E-mail: marianne.boe@idexbiometrics.com Tel: + 47 918 00186 About IDEX Biometrics IDEX Biometrics ASA (OSE: IDEX) is a global technology leader in fingerprint biometrics, offering authentication solutions across payments, access control, and digital identity. Our solutions bring convenience, security, peace of mind and seamless user experiences to the world. Built on
IDEX Biometrics ASA - Private Placement successfully placed – 15 May 202415.5.2024 23:29:12 CEST | Press release
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Oslo, 15 May 2024. Reference is made to the press release from IDEX Biometrics ASA ("IDEX" or the "Company") published earlier today, 15 May 2024, regarding a contemplated private placement of new shares in the Company (the "Offer Shares") to raise gross proceeds of NOK 40-50 million (the "Private Placement"). The Private Placement has been successfully placed. The transaction attracted strong interest and was significantly oversubscribed. On this basis, the Private Placement was upsized to NOK 55 million, through the issue of 33,333,333 new shares (the "Offer Shares") at a price of NOK 1.65 per Offer Share (the "Offer Price"). The net proceeds from the Private Place
Ingredion Incorporated Declares Quarterly Dividend of $0.78 per Share15.5.2024 22:07:18 CEST | Press release
WESTCHESTER, Ill., May 15, 2024 (GLOBE NEWSWIRE) -- Today, the board of directors of Ingredion Incorporated (NYSE: INGR) declared a quarterly dividend of $0.78 per share on the Company’s common stock. The dividend is payable on July 23, 2024, to stockholders of record at the close of business on July 1, 2024. About the Company Ingredion Incorporated (NYSE: INGR), headquartered in the suburbs of Chicago, is a leading global ingredient solutions provider serving customers in nearly 120 countries. With 2023 annual net sales of approximately $8 billion, the Company turns grains, fruits, vegetables, and other plant-based materials into value-added ingredient solutions for the food, beverage, animal nutrition, brewing and industrial markets. With Ingredion Idea Labs® innovation centers located around the world and more than 12,000 employees, the Company co-creates with customers and fulfills its purpose of bringing the potential of people, nature, and technology together to make life better.